A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors
Conclusion VLX600 was reasonably well tolerated and, together with preclinical data, there is support for further efforts to explore its activity as single agent and in combination with drugs or radiation.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Constipation | Drugs & Pharmacology | Investigational New Drugs | Iron | Mitochondrial Disease | Pulmonary Thromboembolism | Study